Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 13/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.63 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.39 |
| ▸ | ABL2 | P42684 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30556508 | 1.00 | TGFBR1 (0.63) | TGFBR1MAPK14AURKAAURKBFTO | |
| SCHEMBL28822071 | 0.90 | TGFBR1 (0.69) | TGFBR1MAPK14AURKAAURKB | |
| SCHEMBL31519383 | 0.86 | TGFBR1 (0.61) | TGFBR1MAPK14AURKAAURKBTHRB | |
| Hydrochloric Acid SCHEMBL23409670 | 0.85 | TGFBR1 (0.60) | TGFBR1MAPK14AURKAAURKBTHRB | |
| SCHEMBL23409664 | 0.85 | TGFBR1 (0.59) | TGFBR1MAPK14AURKAAURKBTHRB | |
| SCHEMBL23409951 | 0.85 | TGFBR1 (0.59) | TGFBR1MAPK14AURKAAURKBTHRB | |
| SCHEMBL29959820 | 0.85 | TGFBR1 (0.59) | TGFBR1MAPK14AURKAAURKBTHRB | |
| SCHEMBL28822090 | 0.85 | TGFBR1 (0.62) | TGFBR1MAPK14THRB | |
| SCHEMBL28822077 | 0.85 | TGFBR1 (0.59) | TGFBR1MAPK14 | |
| SCHEMBL23409854 | 0.84 | TGFBR1 (0.56) | TGFBR1MAPK14AURKAAURKBTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577230-B2 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)- acetamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 | AGOMAB SPAIN S.L.U. (ES) | 2026-03-17 | — | — | US | disclosed |
| US-20230373966-A1 | 2-(3-PYRIDIN-2-YL-4-QUINOLIN-4-YL-PYRAZOL-1-YL)-ACETAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | AGOMAB SPAIN S.L.U. (ES) | 2023-11-23 | — | — | US | disclosed |
| EP-4222149-A1 | 2-(3-PYRIDIN-2-YL-4-QUINOLIN-4-YL-PYRAZOL-1-YL)-ACETAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | AgomAb Spain, S.L.U. (ES) | 2023-08-09 | — | — | EP | disclosed |
| CN-116323601-A | 2- (3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl) -acetamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors | 阿戈麦布西班牙股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577230-B2 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)- acetamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 | TGFBR1, TGFBR2, ACVR1 | TGFBR1 1/4885MAPK14 845/4885AURKA 939/4885 |
| US-20230373966-A1 | 2-(3-PYRIDIN-2-YL-4-QUINOLIN-4-YL-PYRAZOL-1-YL)-ACETAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | ACVR1, ACVRL1, TGFBR2 | TGFBR1 4/4885MAPK14 638/4885AURKA 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.